Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers.
breast cancer
drug development
ovarian cancer
prostate cancer
therapeutics
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
01 Feb 2019
01 Feb 2019
Historique:
received:
13
12
2018
accepted:
14
01
2019
pubmed:
15
1
2019
medline:
15
1
2019
entrez:
15
1
2019
Statut:
ppublish
Résumé
Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the number of deaths from these cancers. These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset. This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers. The review discusses the clinical drugs being used now, promising molecules that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.
Identifiants
pubmed: 30640710
doi: 10.1530/EC-18-0425
pii: EC-18-0425
pmc: PMC6365668
doi:
pii:
Types de publication
Journal Article
Review
Langues
eng
Pagination
R10-R26Références
Nat Clin Pract Urol. 2008 Nov;5(11):610-20
pubmed: 18985049
Nat Rev Urol. 2018 May;15(5):271-286
pubmed: 29460922
Asian J Urol. 2016 Oct;3(4):177-184
pubmed: 28239558
Cancer Treat Rep. 1977 Aug;61(5):899-900
pubmed: 329983
Cancers (Basel). 2018 Dec 04;10(12):
pubmed: 30518089
EMBO Mol Med. 2018 Mar;10(3):
pubmed: 29437778
Clin Cancer Res. 2015 Feb 15;21(4):795-807
pubmed: 25691773
Lancet Oncol. 2016 Jan;17(1):78-89
pubmed: 26590673
Cancer Treat Rev. 2017 Nov;60:130-138
pubmed: 28961554
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
J Evol Biol. 2016 Jun;29(6):1189-200
pubmed: 26991146
JAMA. 2006 Jun 21;295(23):2727-41
pubmed: 16754727
Clin Cancer Res. 2014 Sep 1;20(17):4436-41
pubmed: 24879797
J Clin Oncol. 2017 Apr 1;35(10):1112-1118
pubmed: 28029313
Medicines (Basel). 2018 Feb 01;5(1):
pubmed: 29389895
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
Breast Care (Basel). 2017 May;12(2):102-107
pubmed: 28559767
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer Res. 2012 Mar 15;72(6):1494-503
pubmed: 22266222
J Biol Chem. 2016 Oct 14;291(42):22231-22243
pubmed: 27576691
N Engl J Med. 2010 Sep 2;363(10):943-53
pubmed: 20818904
J Clin Oncol. 2008 Aug 1;26(22):3785-90
pubmed: 18591545
J Clin Oncol. 2016 Jul 1;34(19):2221-31
pubmed: 27044936
Tissue Cell. 1998 Oct;30(5):583-8
pubmed: 9839481
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Curr Treat Options Oncol. 2018 Apr 11;19(5):21
pubmed: 29644491
Clin Interv Aging. 2014 Aug 28;9:1437-52
pubmed: 25210448
N Engl J Med. 2018 Jan 18;378(3):230-240
pubmed: 29342393
Cancer Treat Rep. 1976 Oct;60(10):1431-5
pubmed: 798626
Proteins. 2010 Feb 15;78(3):623-37
pubmed: 19787772
Oncogene. 2015 Apr 2;34(14):1745-57
pubmed: 24837363
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Gynecol Oncol. 2017 Jul;146(1):44-51
pubmed: 28395896
J Cancer. 2011;2:357-9
pubmed: 21716715
J Clin Oncol. 2007 Aug 20;25(24):3621-7
pubmed: 17704411
Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7124-9
pubmed: 27274052
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Lancet Oncol. 2018 Jul;19(7):904-915
pubmed: 29804902
Am J Cancer Res. 2015 Aug 15;5(9):2531-61
pubmed: 26609467
Endocr Rev. 2004 Apr;25(2):235-75
pubmed: 15082521
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Lancet Oncol. 2013 Feb;14(2):134-40
pubmed: 23261356
Ann Oncol. 2016 May;27(5):812-8
pubmed: 27052658
Gynecol Oncol. 2012 Jan;124(1):10-4
pubmed: 21917306
Clin Cancer Res. 2012 Apr 1;18(7):1848-54
pubmed: 22451619
Res Rep Urol. 2018 Feb 16;10:23-32
pubmed: 29497605
J Clin Oncol. 2017 Jan 10;35(2):141-148
pubmed: 28056202
Ann Oncol. 2014 Dec;25(12):2357-2362
pubmed: 25231953
Ther Adv Urol. 2014 Jun;6(3):97-104
pubmed: 24883107
Future Oncol. 2014 Apr;10(5):803-11
pubmed: 24799061
Gynecol Oncol. 2009 May;113(2):205-9
pubmed: 19239974
Curr Treat Options Oncol. 2017 Aug 24;18(10):59
pubmed: 28840453
Cancer Res. 1994 Jan 15;54(2):408-14
pubmed: 8275477
Expert Opin Pharmacother. 2013 Jan;14(1):91-6
pubmed: 23199349
Clin Breast Cancer. 2014 Feb;14(1):1-9
pubmed: 24439786
Breast Cancer. 2016 May;23(3):499-509
pubmed: 25655898
Int J Gynecol Pathol. 2010 May;29(3):203-11
pubmed: 20407318
J Clin Endocrinol Metab. 2008 Mar;93(3):784-91
pubmed: 18073301
Lancet Oncol. 2015 Aug;16(8):928-36
pubmed: 26115797
J Clin Oncol. 2015 Apr 20;33(12):1397-406
pubmed: 25779564
Nat Rev Drug Discov. 2003 Mar;2(3):205-13
pubmed: 12612646
Ther Adv Med Oncol. 2016 Jul;8(4):267-75
pubmed: 27482286
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Clin Cancer Res. 2013 Oct 1;19(19):5505-12
pubmed: 23965901
Med Oncol. 2017 Jun;34(6):103
pubmed: 28444622
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):152-6
pubmed: 23271766
J Clin Oncol. 2014 Oct 20;32(30):3374-82
pubmed: 25225436
J Clin Oncol. 2009 Jul 20;27(21):3459-64
pubmed: 19433685
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Gynecol Oncol. 2016 Oct;143(1):27-34
pubmed: 27546885
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Eur J Med Chem. 2018 Jan 1;143:515-531
pubmed: 29207335
Mol Cancer Res. 2017 Jun;15(6):660-669
pubmed: 28209757
Br J Cancer. 1971 Jun;25(2):270-5
pubmed: 5115829
P T. 2012 Aug;37(8):440-8
pubmed: 23091336
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Lancet. 2013 Mar 9;381(9869):805-16
pubmed: 23219286
Lancet Oncol. 2013 Sep;14(10):1020-6
pubmed: 23948349
Cancer Treat Rev. 2015 Jul;41(7):588-97
pubmed: 25981454
Cancer Res. 2011 Sep 15;71(18):6019-29
pubmed: 21799031
N Engl J Med. 2018 Jan 18;378(3):293-294
pubmed: 29342385
Cancer Res. 2009 May 15;69(10):4434-42
pubmed: 19366804
Cancer Res. 2017 Nov 15;77(22):6282-6298
pubmed: 28978635
J Clin Oncol. 2003 Jan 15;21(2):283-90
pubmed: 12525520
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
Iowa Med. 1992 Dec;82(12):479
pubmed: 1464524
Cancer Cell. 2010 Jun 15;17(6):535-46
pubmed: 20541699
J Endocrinol. 1987 Jun;113(3):R7-9
pubmed: 3625091
J Med Chem. 2018 Jan 25;61(2):543-575
pubmed: 28594553
Br J Cancer. 1996 Jul;74(2):300-8
pubmed: 8688341
J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):237-47
pubmed: 15860266
Curr Probl Cancer. 2016 Mar - Aug;40(2-4):141-150
pubmed: 27816190
Expert Opin Biol Ther. 2017 Mar;17(3):365-374
pubmed: 28092723
Anticancer Agents Med Chem. 2007 Jan;7(1):111-23
pubmed: 17266508
Clin Cancer Res. 2007 Jun 15;13(12):3617-22
pubmed: 17575226
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
Oncotarget. 2017 Sep 12;8(49):85997-86010
pubmed: 29156772
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Adv Anat Pathol. 2009 Sep;16(5):267-82
pubmed: 19700937
J Clin Oncol. 2003 Sep 1;21(17):3194-200
pubmed: 12860964
Onco Targets Ther. 2013 Apr 16;6:391-402
pubmed: 23620672
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Eur J Cancer (1965). 1980 Feb;16(2):239-51
pubmed: 6768559
Curr Oncol. 2015 Feb;22(1):10-2
pubmed: 25684983
Clin Cancer Res. 2002 Mar;8(3):665-9
pubmed: 11895893
Lancet Oncol. 2017 Jun;18(6):732-742
pubmed: 28526536
Clin Cancer Res. 2015 Mar 15;21(6):1273-80
pubmed: 25320358
Front Oncol. 2018 Apr 03;8:89
pubmed: 29670855
Elife. 2013 Apr 09;2:e00499
pubmed: 23580326
Br J Cancer. 2017 Feb 14;116(4):455-463
pubmed: 28118323
Clin Pharmacol Ther. 2015 Dec;98(6):582-9
pubmed: 26331358
Ann Oncol. 2018 Jul 1;29(7):1541-1547
pubmed: 29718092
N Engl J Med. 1996 Jan 4;334(1):1-6
pubmed: 7494563
Curr Pharm Des. 2017;23(28):4170-4179
pubmed: 28183249
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Curr Drug Targets. 2012 Sep 1;13(10):1308-23
pubmed: 22746994
Eur J Cancer. 2017 Jan;70:111-121
pubmed: 27914241
Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38
pubmed: 29249039
Int J Gynaecol Obstet. 2004 Sep;86(3):371-6
pubmed: 15325855
Pharmacogenomics. 2017 Nov;18(17):1595-1609
pubmed: 29095114
N Engl J Med. 1990 Apr 12;322(15):1021-7
pubmed: 2181310
J Investig Med. 2012 Feb;60(2):504-7
pubmed: 22064602
Br J Cancer. 2011 Mar 29;104(7):1059-66
pubmed: 21364577
J Clin Oncol. 2017 Apr 1;35(10):1041-1048
pubmed: 28113032
Clin Breast Cancer. 2005 Apr;6 Suppl 1:S5-8
pubmed: 15865849
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Expert Rev Anticancer Ther. 2008 Jul;8(7):1073-9
pubmed: 18588452
Lancet. 1995 Feb 25;345(8948):525
pubmed: 7861903
Cancer. 2016 Jun 15;122(12):1897-904
pubmed: 27019001
Cancer Treat Rev. 2012 May;38(3):212-7
pubmed: 21726959
Gynecol Oncol. 2015 Apr;137(1):173-9
pubmed: 25677064
N Engl J Med. 2018 Jul 12;379(2):122-137
pubmed: 29863451
Asian J Urol. 2018 Jan;5(1):28-32
pubmed: 29379733
Breast Cancer Res. 2016 Jun 28;18(1):67
pubmed: 27349747
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
JAMA Oncol. 2017 Sep 01;3(9):1266-1273
pubmed: 28301631
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882